和鉑醫藥-B(02142.HK)完成向最後一名患者以巴託利單抗(HBM9161)Ib/IIa期試驗治療視神經脊髓炎譜系疾病首次給藥
格隆匯7月16日丨和鉑醫藥-B(02142.HK)發佈公吿,巴託利單抗(HBM9161,為一款抗FcRn 抗體,併為由公司開發用於自身免疫性疾病療法的新型藥物)用於治療急性視神經脊髓炎譜系疾病的臨牀試驗已完成Ib/IIa期試驗中最後一名患者的首次給藥。該臨牀試驗旨在評估巴託利單抗 (HBM9161)在治療中國視神經脊髓炎譜系疾病患者時的安全性、耐受性、藥效及療效。該臨牀試驗為首個有關治療視神經脊髓炎譜系疾病的抗FcRn概念驗證研究。
巴託利單抗(HBM9161)阻斷免疫球蛋白G(“IgG”)(包括致病性IgG)與新生兒Fc 受體(“FcRn”)的結合,並大幅降低體內的IgG水平,從而治療以自身抗體為介導的自身免疫性疾病,包括視神經脊髓炎譜系疾病。作為產品管線的一部分,公司正在開發巴託利單抗(HBM9161),用於治療多種有大量未獲滿足醫療需求的且由致病性IgG介導的自身免疫性疾病。公司正於中國針對適應症開發候選藥物,而視神經脊髓炎譜系疾病為當中最早展開研究的適應症之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.